Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


09.07.2018

1 AJR Am J Roentgenol
1 Am J Clin Oncol
9 Ann Surg Oncol
5 Anticancer Res
2 BMC Cancer
2 Breast Cancer
2 Breast Cancer Res
7 Breast Cancer Res Treat
1 Cancer
2 Cancer Lett
1 Cancer Res
2 Eur J Surg Oncol
1 Gene
1 Histopathology
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
3 Oncogene
3 PLoS One
2 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. MALTEZ DE ALMEIDA JR
    Work in Progress: Subdividing MRI BI-RADS Category 4 Assessment.
    AJR Am J Roentgenol. 2017;209:W401.
    PubMed     Text format    


    Am J Clin Oncol

  2. LEONE JP, Haraldsson B, Mott SL, McDowell BD, et al
    Treatment Patterns and Survival of Elderly Patients With Breast Cancer Brain Metastases.
    Am J Clin Oncol. 2018 Jun 30. doi: 10.1097/COC.0000000000000477.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  3. YAO K, Boughey JC
    'Nudging' Surgeons and Patients to De-Escalation of Surgery for Breast Cancer.
    Ann Surg Oncol. 2018 Jul 2. pii: 10.1245/s10434-018-6588.
    PubMed     Text format    

  4. BELLO DM, Russell C, McCullough D, Tierno M, et al
    Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
    Ann Surg Oncol. 2018 Jul 2. pii: 10.1245/s10434-018-6598.
    PubMed     Text format     Abstract available

  5. TAMIRISA N, Thomas SM, Fayanju OM, Greenup RA, et al
    Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival.
    Ann Surg Oncol. 2018 Jul 2. pii: 10.1245/s10434-018-6595.
    PubMed     Text format     Abstract available

  6. BLEICHER RJ
    Timing and Delays in Breast Cancer Evaluation and Treatment.
    Ann Surg Oncol. 2018 Jul 2. pii: 10.1245/s10434-018-6615.
    PubMed     Text format     Abstract available

  7. OLLILA DW, Hwang ES, Brenin DR, Kuerer HM, et al
    The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations.
    Ann Surg Oncol. 2018 Jul 2. pii: 10.1245/s10434-018-6618.
    PubMed     Text format     Abstract available

  8. TEVIS SE, James TA, Kuerer HM, Pusic AL, et al
    Patient-Reported Outcomes for Breast Cancer.
    Ann Surg Oncol. 2018 Jul 3. pii: 10.1245/s10434-018-6616.
    PubMed     Text format     Abstract available

  9. GARCIA D, Spruill LS, Irshad A, Wood J, et al
    The Value of a Second Opinion for Breast Cancer Patients Referred to a National Cancer Institute (NCI)-Designated Cancer Center with a Multidisciplinary Breast Tumor Board.
    Ann Surg Oncol. 2018 Jul 3. pii: 10.1245/s10434-018-6599.
    PubMed     Text format     Abstract available

  10. XU Y, Bouchard-Fortier A, Olivotto IA, Cheung WY, et al
    'Driving' Rates Down: A Population-Based Study of Opening New Radiation Therapy Centers on the Use of Mastectomy for Breast Cancer.
    Ann Surg Oncol. 2018 Jul 3. pii: 10.1245/s10434-018-6619.
    PubMed     Text format     Abstract available

  11. LANDERCASPER J
    Why Do Reoperation Rates Vary So Much After Lumpectomy for Breast Cancer? Examining the Reoperation Puzzle at the Massachusetts General Hospital.
    Ann Surg Oncol. 2018 Jul 3. pii: 10.1245/s10434-018-6609.
    PubMed     Text format    


    Anticancer Res

  12. CHIANG KC, Yeh CN, Yeh TS, Juang HH, et al
    MART-10, a 1alpha,25(OH)2D3 Analog, Potently Represses Metastasis of ER(+) Breast Cancer Cells with VEGF-A Overexpression.
    Anticancer Res. 2018;38:3879-3887.
    PubMed     Text format     Abstract available

  13. SAKAGUCHI K, Nakatsukasa K, Koyama H, Kato M, et al
    Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:4073-4081.
    PubMed     Text format     Abstract available

  14. KUBO M, Umebayashi M, Kurata K, Mori H, et al
    Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:4273-4279.
    PubMed     Text format     Abstract available

  15. TANAKA T, Uchida H
    Inhibition of Survivin by Adenovirus Vector Enhanced Paclitaxel-induced Apoptosis in Breast Cancer Cells.
    Anticancer Res. 2018;38:4281-4288.
    PubMed     Text format     Abstract available

  16. MORI H, Kubo M, Kai M, Kurata K, et al
    Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Anticancer Res. 2018;38:4381-4386.
    PubMed     Text format     Abstract available


    BMC Cancer

  17. REAL SAS, Parveen F, Rehman AU, Khan MA, et al
    Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients.
    BMC Cancer. 2018;18:711.
    PubMed     Text format     Abstract available

  18. RANGEL N, Fortunati N, Osella-Abate S, Annaratone L, et al
    FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    BMC Cancer. 2018;18:703.
    PubMed     Text format     Abstract available


    Breast Cancer

  19. MA D, Chen C, Wu J, Wang H, et al
    Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
    Breast Cancer. 2018 Jul 5. pii: 10.1007/s12282-018-0891.
    PubMed     Text format     Abstract available

  20. TOKUNAGA E, Fujita A, Takizawa K, Baba K, et al
    CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer. 2018 Jul 3. pii: 10.1007/s12282-018-0888.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  21. SJOSTROM M, Staaf J, Eden P, Warnberg F, et al
    Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
    Breast Cancer Res. 2018;20:64.
    PubMed     Text format     Abstract available

  22. CHANG XZ, Li DQ, Hou YF, Wu J, et al
    Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
    Breast Cancer Res. 2018;20:63.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  23. KABIL N, Bayraktar R, Kahraman N, Mokhlis HA, et al
    Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4847.
    PubMed     Text format     Abstract available

  24. ANGARITA FA, Elmi M, Zhang Y, Look Hong NJ, et al
    Patient-reported factors influencing the treatment decision-making process of older women with non-metastatic breast cancer: a systematic review of qualitative evidence.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4865.
    PubMed     Text format     Abstract available

  25. ROBINSON A, Souied O, Bota AB, Levasseur N, et al
    Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4868.
    PubMed     Text format     Abstract available

  26. WANG J, Xu B, Wang W, Zhai X, et al
    Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4867.
    PubMed     Text format     Abstract available

  27. NIKOLIC D, Granic M, Ivanovic N, Zdravkovic D, et al
    Breast cancer and its impact in male transsexuals.
    Breast Cancer Res Treat. 2018 Jul 5. pii: 10.1007/s10549-018-4875.
    PubMed     Text format     Abstract available

  28. BERTHE A, Zaffino M, Muller C, Foulquier F, et al
    Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4874.
    PubMed     Text format     Abstract available

  29. SAGARA Y, Takada M, Ohi Y, Ohtani S, et al
    Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4873.
    PubMed     Text format     Abstract available


    Cancer

  30. DASH C, Taylor TR, Makambi KH, Hicks J, et al
    Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE study.
    Cancer. 2018 Jul 5. doi: 10.1002/cncr.31569.
    PubMed     Text format     Abstract available


    Cancer Lett

  31. XIAO Y, Li Y, Tao H, Humphries B, et al
    Integrin alpha5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Cancer Lett. 2018 Jun 29. pii: S0304-3835(18)30445.
    PubMed     Text format     Abstract available

  32. GU J, Wang Y, Wang X, Zhou D, et al
    Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer.
    Cancer Lett. 2018 Jun 30. pii: S0304-3835(18)30447.
    PubMed     Text format     Abstract available


    Cancer Res

  33. XING Z, Zhang Y, Liang K, Yan L, et al
    Expression of long non-coding RNA YIYA promotes glycolysis in breast cancer.
    Cancer Res. 2018 Jul 2. pii: 0008-5472.CAN-17-0385.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  34. ROBERTSON SA, Cutress RI
    Mastectomy skin flap thickness.
    Eur J Surg Oncol. 2018;44:1118.
    PubMed     Text format    

  35. MARTA GN, Poortmans P, de Barros AC, Filassi JR, et al
    Reply to: Mastectomy skin flap thickness.
    Eur J Surg Oncol. 2018;44:1119-1120.
    PubMed     Text format    


    Gene

  36. AL-OTHMAN N, Hammad H, Ahram M
    Dihydrotestosterone regulates expression of CD44 via miR-328-3p in triple-negative breast cancer cells.
    Gene. 2018 Jun 28. pii: S0378-1119(18)30755-8. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available


    Histopathology

  37. CAO L, Li C, Xu C, Xiang G, et al
    Clinical significance of PDEF factor expression and its relation to androgen receptor in ER(-) breast cancer.
    Histopathology. 2018 Jul 3. doi: 10.1111/his.13699.
    PubMed     Text format     Abstract available


    Int J Cancer

  38. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Text format     Abstract available

  39. KISO M, Tanaka S, Saji S, Toi M, et al
    Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31645.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  40. KAISER J, Kronberger C, Moder A, Kopp P, et al
    Intraoperative Tumor Bed Boost With Electrons in Breast Cancer of Clinical Stages I Through III: Updated 10-Year Results.
    Int J Radiat Oncol Biol Phys. 2018 May 17. pii: S0360-3016(18)30823.
    PubMed     Text format     Abstract available


    Oncogene

  41. CUI YH, Kim H, Lee M, Yi JM, et al
    FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
    Oncogene. 2018 Jul 4. pii: 10.1038/s41388-018-0372.
    PubMed     Text format     Abstract available

  42. DU WW, Yang W, Li X, Awan FM, et al
    A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy.
    Oncogene. 2018 Jul 4. pii: 10.1038/s41388-018-0369.
    PubMed     Text format     Abstract available

  43. GOLFMANN K, Meder L, Koker M, Volz C, et al
    Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
    Oncogene. 2018 Jul 3. pii: 10.1038/s41388-018-0380.
    PubMed     Text format     Abstract available


    PLoS One

  44. TAKABAYASHI M, Majeed H, Kajdacsy-Balla A, Popescu G, et al
    Disorder strength measured by quantitative phase imaging as intrinsic cancer marker in fixed tissue biopsies.
    PLoS One. 2018;13:e0194320.
    PubMed     Text format     Abstract available

  45. CHEN Z, Ai L, Mboge MY, Tu C, et al
    Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.
    PLoS One. 2018;13:e0199476.
    PubMed     Text format     Abstract available

  46. WITTKOWSKI KM, Dadurian C, Seybold MP, Kim HS, et al
    Complex polymorphisms in endocytosis genes suggest alpha-cyclodextrin as a treatment for breast cancer.
    PLoS One. 2018;13:e0199012.
    PubMed     Text format     Abstract available


    Radiother Oncol

  47. MONTEN C, Lievens Y
    Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?
    Radiother Oncol. 2018;126:132-138.
    PubMed     Text format     Abstract available

  48. HAVILAND JS, Mannino M, Griffin C, Porta N, et al
    Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.
    Radiother Oncol. 2018;126:155-162.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: